Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT (2022 - 2025)

Stoke Therapeutics has reported EBIT over the past 4 years, most recently at -$61.4 million for Q4 2025.

  • Quarterly results put EBIT at -$61.4 million for Q4 2025, down 350.0% from a year ago — trailing twelve months through Dec 2025 was -$20.6 million (up 79.69% YoY), and the annual figure for FY2025 was -$20.6 million, up 79.69%.
  • EBIT for Q4 2025 was -$61.4 million at Stoke Therapeutics, down from -$43.1 million in the prior quarter.
  • Over the last five years, EBIT for STOK hit a ceiling of $111.2 million in Q1 2025 and a floor of -$61.4 million in Q4 2025.
  • Median EBIT over the past 4 years was -$27.3 million (2023), compared with a mean of -$21.3 million.
  • Peak annual rise in EBIT hit 492.08% in 2025, while the deepest fall reached 350.0% in 2025.
  • Stoke Therapeutics' EBIT stood at -$27.2 million in 2022, then decreased by 8.87% to -$29.6 million in 2023, then surged by 53.85% to -$13.7 million in 2024, then tumbled by 350.0% to -$61.4 million in 2025.
  • The last three reported values for EBIT were -$61.4 million (Q4 2025), -$43.1 million (Q3 2025), and -$27.3 million (Q2 2025) per Business Quant data.